Sepsis recombinant human activated protein

Bernard GR, Vincent JL, Laterre PF, et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 699-709. 

Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med 2004 32 S239-S246. 

Recombinant human activated protein C, the first anti-inflammatory agent to be approved for sepsis, promotes fibrinolysis and associated anti-inflammatory mechanisms. The Recombinant Human Activated Protein C Worldwide Evalnation in Severe Sepsis (PROWESS) trial studied the effects of 96 hours of continuous infusion of recombinant activated protein C. AU-canse mortality at 28 days was rednced significantly from 30.8% with placebo to 24.7% in those receiving activated protein C. 

Eichacker RQ, Natanson C. Recombinant human activated protein C in sepsis Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 2003 31 594-96. 

Drotrecogin is a recombinant human activated protein C that exerts an antithrombotic effect by inhibiting factor Va and factor Villa. It is indicated in the reduction of mortality in adult patients with severe sepsis who have a high risk of death. Drotrecogin alfa Drotrecogin alfa (Xigris) is a recombinant form of human activated protein C that inhibits coagulation by proteolytic inactivation of factor Va and factor Villa. It also has antiinflammatory effects. A 96-hour continuous infusion... 

Recombinant-human activated protein C Severe sepsis Academisch Medisch Centrum-Universiteit van Amsterdam (AMC-UvA)... 

---